http://online.wsj.com/article/PR-CO-20130805-904476.html?mod=googlenews_wsj
Avita Medical Ltd Expected to Dominate Market for Burns and Scalds Treatment, Says Zacks Analyst via Interview With The Life Sciences Report
SAN FRANCISCO, CA--(Marketwired - Aug 5, 2013) - Jason Napodano, Senior Biotechnology Analyst at Zacks Investment Research, stated in an interview with George Mack of The Life Sciences Report, "Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY) has a regenerative medicine device product called ReCell(R) Spray-On Skin(R) (autologous cell suspension), a treatment for severe skin defects, burns, scalds, scars, vitiligo (discoloration of ...
wall street journal avita to dominate
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.38 |
Change
0.010(0.42%) |
Mkt cap ! $162.0M | |||
| Open | High | Low | Value | Volume |
| $2.39 | $2.41 | $2.36 | $275.0K | 115.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20068 | $2.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.40 | 43 | 1 |
View Market Depth
| Last trade - 16.10pm 08/07/2024 (20 minute delay) ? |
| AVH (ASX) Chart |